0000769993-20-000004.txt : 20200106 0000769993-20-000004.hdr.sgml : 20200106 20200106191416 ACCESSION NUMBER: 0000769993-20-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200106 DATE AS OF CHANGE: 20200106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jones Adrian M CENTRAL INDEX KEY: 0001359316 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36571 FILM NUMBER: 20511671 MAIL ADDRESS: STREET 1: C/O GOLDMAN, SACHS & CO. STREET 2: 85 BROAD STREET CITY: NEW YORK STATE: NY ZIP: 10004 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: T2 Biosystems, Inc. CENTRAL INDEX KEY: 0001492674 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204827488 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-457-1200 MAIL ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 ownershipdoc01022020024513.xml X0306 4 2020-01-02-05:00 false 0001492674 T2 Biosystems, Inc. TTOO 0001359316 Jones Adrian M C/O GOLDMAN SACHS & CO. LLC 200 WEST STREET NEW YORK NY 10282 true false false false Common Stock 2020-01-02-05:00 4 A false 34188 0 A 4270641 I See footnotes Non-Qualified Stock Option (Right to Buy) 8.92 2026-03-09-04:00 Common Stock 66176 66176 I See footnotes Stock Option (Right to Buy) 1.54 2029-06-07-04:00 Common Stock 22000 22000 I See footnotes The Reporting Person is a managing director of Goldman Sachs & Co. LLC ("Goldman Sachs"). Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. The 34,188 shares of common stock, par value $0.001 per share (the "Common Stock"), were granted pursuant to T2 Biosystems, Inc.'s (the "Company") Amended and Restated 2014 Incentive Award Plan under the Company's Non-Employee Director Compensation Program (the "Plan"), consisting of 34,188 restricted stock units granted to the Reporting Person in his capacity as a director of the Company. The grant of 34,188 restricted stock units shall become fully vested on January 2, 2021, subject to the Reporting Person continuing in service on the Company's board of directors through such vesting date. Each restricted stock unit represents a contingent right to receive one share of the Company's Common Stock. The Reporting Person has an understanding with GS Group pursuant to which he holds such securities for the benefit of GS Group. GS Group may be deemed to beneficially own 4,270,641 shares of common stock by reason of 34,188 restricted stock units that were granted to the Reporting Person pursuant to the Plan. GS Group and Goldman Sachs may be deemed to beneficially own indirectly, in the aggregate, 4,157,240 shares of common stock of the Company by reason of the direct beneficial ownership of common stock by certain investment entities (the "GS Funds") because GS Group, or affiliates of GS Group and Goldman Sachs, are the general partner, managing general partner, managing partner, managing member or member of each of the GS Funds. Goldman Sachs beneficially owns directly and GS Group may be deemed to beneficially own indirectly 29,216 shares of common stock. The options to purchase 66,176 shares of common stock of the Company were granted to the Reporting Person in his capacity as a director of the Company pursuant to the Plan. The options vested on March 9, 2019. The Reporting Person has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group. The options to purchase 22,000 shares of common stock of the Company were granted to the Reporting Person, pursuant to Plan on June 7, 2019 in his capacity as a director of the Company. The options vest and become exercisable in twelve substantially equal monthly installments commencing on June 7, 2019.The Reporting Person has an understanding with GS Group pursuant to which he holds such options for the benefit of GS Group. /s/ Jamison Yardley, Attorney-in-fact 2020-01-06-05:00